Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2003

Study Completion Date

October 31, 2005

Conditions
Lymphoma, Non-HodgkinLymphoma, Low-Grade
Interventions
DRUG

ibritumomab tiuxetan (Zevalin®)

Trial Locations (8)

Unknown

Loma Linda University, Loma Linda

North County Oncology, Oceanside

Medical Specialists of Fairfield, Fairfield

Queens Hospital, Honolulu

Northwest Oncology and Hematology, Elk Grove Village

Horizon Oncolgy Center, Lafayette

Specialists in Hematology/Oncology, St Louis

Presbyterian Hospital Cancer Center, Charlotte

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00168727 - Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter